Results 161 to 170 of about 6,976 (207)

Early-Phase Oral Antiviral Use and Post-COVID-19 Condition in Outpatients.

JAMA Netw Open
Hibino M, Shintani A, Murayama H, Morikawa N, Maeda K, Nishiguchi S, Monma E, Harada H, Takagi T, Kuroyanagi S, Endo K, Terada Y, Kinoshita M, Yoden T, Miyazawa S, Higashiue S.   +15 more
europepmc   +1 more source

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses [PDF]

Virology, 2021
Endemic seasonal coronaviruses cause morbidity and mortality in a subset of patients, but no specific treatment is available. Molnupiravir is a promising pipeline antiviral drug for treating SARS-CoV-2 infection potentially by targeting RNA-dependent RNA
Mirza S Baig, Maikel P Peppelenbosch, Qiuwei Pan   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Molnupiravir for the treatment of COVID-19

Drugs of Today, 2022
Molnupiravir (MK-4482, EIDD-2801) is a promising broad-spectrum experimental antiviral developed by Merck & Co. It is a nucleoside analogue prodrug that undergoes rapid conversion into nucleoside triphosphate (NTP) by intracellular metabolic processes. NTP inhibits viral polymerase by acting as an alternative substrate.
Bela G, Santani, Brian W, LeBlanc, Ritesh P, Thakare   +2 more
openaire   +2 more sources

Molnupiravir: From Hope to Epic Fail?

Viruses, 2022
Molnupiravir has been the first oral antiviral authorized for COVID-19 outpatients, reporting extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far.
Daniele Focosi
exaly   +2 more sources

Molnupiravir is effective in patients with haematological malignancies

International Journal of Cancer, 2023
AbstractPatients with hematologic malignancies are particularly vulnerable to severe infectious complications. SARS‐CoV‐2 infection is associated with a high risk of severe course and death in this patient population. In addition, immune deficits associated with both the blood cancer and the treatment used make vaccination against SARS‐CoV‐2 less ...
Łukasz Bołkun, Bartosz Pula, Agnieszka Kołkowska‐Leśniak, Marta Morawska, Edyta Cichocka, Grzegorz Charlinski, Bartosz Garus, Sebastian Giebel, Jaroslaw Piszcz, Joanna Drozd‐Sokolowska, Jacek Kwiatkowski, Monika Biernat, Iwona Hus, Ewa Lech‐Maranda, Monika Długosz‐Danecka, Krzysztof Giannopoulos, Tomasz Wróbel   +16 more
openaire   +2 more sources

Molnupiravir in COVID-19: A Scoping Review

Current Drug Research Reviews, 2022
Background: COVID-19, first detected in Wuhan, China, has evolved into a lifethreatening pandemic spread across six continents, with the global case count being more than 243 million, and mortality over 4.95 million, along with causing significant morbidity.
Shubham Atal, Shilpa Kaore
openaire   +2 more sources

Molnupiravir

Reactions Weekly, 2023
  +4 more sources

Molnupiravir/sotrovimab

Reactions Weekly, 2023
  +4 more sources